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ABSTRACT	  
BACKGROUND	  AND	  OBJECTIVS:	  
Congenital	   anomalies	   of	   kidneys	   and	   urinary	   tract	   (CAKUT)	   are	   the	   most	   predominant	   developmental	  
disorders	  comprising	  ≈20-­‐30%	  of	  all	  anomalies	   identified	   in	   the	  prenatal	  period.	  Mutations	   in	  hepatocyte	  
nuclear	  factor	  1-­‐beta	  (HNF1B)	  involved	  in	  the	  development	  of	  kidneys,	  liver,	  pancreas	  and	  urogenital	  tract	  
are	   the	   most	   frequent	   monogenetic	   cause	   of	   CAKUT	   found	   in	   approximately	   10-­‐30%	   of	   the	   patients	  
depending	   on	   screening	   policy	   and	   study	   design.	  We	   aimed	   to	   define	   criteria	   for	   analysis	   of	  HNF1B	   in	   a	  
prospective	  cohort	  of	  CAKUT	  patients.	  
	  
DESIGN,	  SETTING,	  PARTICIPANTS	  AND	  MEASUREMENTS	  
We	  included	  CAKUT	  patients	  diagnosed	  in	  our	  paediatric	  and	  adult	  nephrology	  departments	  from	  January	  
2013	  until	  April	  2013	  bases	  on	  predefined	  screening	  criteria.	  Subjects	  presenting	  with	  at	   least	  one	  major	  
renal	  criterion	  or	  one	  minor	  renal	  criterion	  with	  one	  or	  more	  extra-­‐renal	  criteria	  in	  the	  personal	  or	  familial	  
history	  were	  considered	  eligible.	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RESULTS	  
We	  prospectively	  screened	  205	  patients	  and	  detected	  HNF1B	  mutations	  in	  10%	  (n=20,	  12	  children,	  median	  
age	  4.2	   (range	  0-­‐13.1)	   and	  8	   adults	   (median	   age	  34.8	   (range	  16.6-­‐62)	   years).	  We	  observed	   that	   bilateral	  
renal	   anomaly,	   renal	   cysts	   from	   unknown	   origin,	   a	   combination	   of	   two	   major	   renal	   criteria,	   and	  




We	  demonstrated	  that	  HNF1B	  mutations	  are	  responsible	  for	  ≈10%	  of	  CAKUT	  cases,	  both	  in	  children	  and	  in	  
adults.	  Based	  on	  our	  results	  we	  propose	  adapted	  criteria	  for	  HNF1B	  analysis	  to	  reduce	  the	  screening	  costs	  
without	  missing	  affected	  patients.	  These	  criteria	  should	  be	  reaffirmed	  in	  a	  larger	  validation	  cohort.	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ABBREVIATIONS	  
CAKUT	   	   congenital	  anomalies	  of	  kidney	  and	  urinary	  tract	  
HNF1B	   	   hepatocyte	  nuclear	  factor	  1-­‐beta	  	  
TCF2	   	   transcription	  factor	  2	  
MODY	   	   maturity	  onset	  diabetes	  of	  the	  young	  
RCAD	   	   renal	  cysts	  and	  diabetes	  syndrome	  
VUR	   	   vesico-­‐uretral	  reflux	  





   
INTRODUCTION	  	  
Congenital	  anomalies	  of	  kidneys	  and	  urinary	  tract	  (CAKUT)	  are	  the	  most	  frequent	  developmental	  disorders	  
in	  humans	  and	  remain	  the	  leading	  cause	  of	  chronic	  kidney	  disease	  in	  childhood	  [1].	  The	  aetiology	  of	  CAKUT	  
is	   heterogeneous	   and	   involves	   genetic,	   epigenetic	   and	   environmental	   factors	   [2,	   3].	   A	   multitude	   of	  
monogenetic	   disorders	   have	   been	   identified	   in	   CAKUT	   cases	   with	   mutations	   in	   the	   hepatocyte	   nuclear	  
factor	  1	  beta	  (HNF-­‐1β)	  being	  currently	  the	  most	  frequently	  reported	  underlying	  genetic	  cause	  [3].	  
HNF-­‐1β	   belongs	   to	   the	   homeodomain-­‐containing	   family	   of	   transcription	   factors	   encoded	   by	   the	  
transcription	   factor	   2	   (TCF2	   or	   HNF1B)	   gene	   located	   on	   chromosome	   17	   and	   is	   involved	   in	   the	  
organogenesis	   of	   kidneys,	   urinary	   tract,	   liver	   and	   pancreas.	   HNF-­‐1β	   functions	   as	   a	   homodimer	   or	   a	  
heterodimer	  with	  structurally	  related	  HNF-­‐1α	  [4].	  While	  mutations	  in	  HNF-­‐1α	  are	  the	  most	  frequent	  genetic	  
cause	  of	  the	  maturity	  onset	  diabetes	  of	  the	  young	  (MODY)	  [5],	  renal	  malformations	  (CAKUT)	  are	  specific	  for	  
HNF-­‐1β	  [5]	  and	  can	  occur	  either	  in	  combination	  with	  MODY	  (coined	  as	  renal	  cysts	  and	  diabetes	  syndrome,	  
RCAD	  or	  MODY5),	   liver	  disease,	  hyperuricemia,	  pancreas	  atrophy	  or	  be	   isolated	  [6].	  Although	  the	  HNF1B-­‐
associated	  disorders	  are	  characterized	  by	  an	  autosomal	  dominant	  inheritance,	  there	  is	  a	  high	  heterogeneity	  
in	   phenotype,	   even	   between	   individuals	   with	   the	   same	   inherited	   mutation	   [7-­‐9].	   Therefore,	   selection	  
criteria	  for	  HNF1B	  genetic	  analysis	  are	  not	  well	  defined	  and	  the	  percentage	  of	  HNF1B	  mutations	  in	  patients	  
with	  CAKUT	  varies	  largely	  between	  10	  and	  30%	  depending	  on	  screening	  policy	  and	  study	  design	  [8,	  10,	  11].	  
Retrospective	  studies	  and	  inclusion	  of	  more	  family	  members	  might	  probably	  increase	  this	  percentage.	  	  
Renal	  manifestations	  are	  observed	  in	  almost	  all	  patients	  with	  HNF1B	  mutations	  and	  encompass	  a	  spectrum	  
of	  abnormalities	  either	  isolated	  or	  in	  combination	  with	  extra-­‐renal	  manifestations	  (Table	  1)	  [8-­‐10,	  12-­‐15].	  	  
In	  this	  study	  we	  aimed	  to	  test	  published	  criteria	  for	  analysis	  of	  HNF1B	  in	  a	  prospective	  single	  centre	  cohort	  
of	  incident	  paediatric	  and	  adult	  patients	  with	  CAKUT.	  	  Based	  on	  these	  results	  we	  propose	  adapted	  criteria	  





   
MATERIALS	  AND	  METHODS	  
Patients	  
We	   prospectively	   included	   CAKUT	   patients	   from	   the	   paediatric	   and	   adult	   nephrology	   department	   from	  
January	   2010	   until	   April	   2013	   having	   at	   least	   one	   major	   renal	   anomaly	   (fetal	   bilateral	   hyperechogenic	  
kidneys,	   multicystic	   dysplastic	   kidney	   (MCDK),	   renal	   agenesis,	   hypoplastic	   or	   dysplastic	   kidneys,	   cysts	   of	  
unknown	   origin)	   or	   one	   minor	   renal	   (ectopic	   kidney,	   vesico-­‐ureteral	   reflux	   (VUR),	   hydronephrosis)	  
combined	   with	   one	   or	   more	   extra-­‐renal	   anomalies	   associated	   with	   HNF1B	   mutations	   (MODY,	  
hypomagnesaemia,	  liver	  function	  anomalies)	  in	  the	  personal	  history	  or	  a	  familial	  history	  	  of	  renal	  or	  extra-­‐
renal	  manifestations	  (Table	  1).	  	  
The	  diagnosis	  of	  CAKUT	  was	  made	  by	  renal	  ultrasound	  (US)	  in	  all	  patients;	  micturating	  cystourethrogram	  or	  
nuclear	   scans	  were	   considered	   in	   the	  diagnosis	   if	   applicable.	  Antenatal	   diagnosis	   of	   CAKUT	  was	  made	   in	  
85/147	  of	   the	  children	  and	   in	  1/58	  adults.	  Two	  hundred	  and	   five	  patients	   (147	  <16	  years	  old	  and	  58	  >16	  
years	  old;	  120	  males)	  were	  included	  in	  final	  analysis.	  	  
Biochemical	  investigations	  
We	   analysed	   electrolytes,	   creatinine,	   albumin,	   glucose	   and	   liver	   enzymes	   in	   serum/plasma	   and	   urine	  
electrolytes,	  glucose,	  protein	  and	  creatinine	  by	  routine	  laboratory	  procedures.	  Hyperuricemia	  was	  defined	  
as	   	   >5.7	  mmol/l	   in	   females	   and	  >7	  mmol/l	   in	  males,	   hypomagnesaemia	  was	  defined	  as	   <0.6	  mmol/l	   and	  
corrected	   for	   age,	   hypokalemia	   was	   defined	   as	   <3.5	   mmol/l.	   Creatinine	   clearance	   was	   calculated	   using	  
Schwartz	  equation	  for	  children	  [16]	  and	  Cockcroft-­‐Gault	  formula	  for	  adults	  [17].	  	  
Genetic	  analysis	  	  
DNA	  was	  isolated	  from	  blood	  samples	  using	  standard	  methods.	  Primers	  were	  designed	  to	  cover	  all	  coding	  
exons	   of	   the	   HNF1B	   gene	   (NM_000458.2),	   including	   exon–intron	   boundaries.	   Primer	   sequences	   are	  
available	  on	   request.	   75	  ng	  of	   genomic	  DNA	  was	  amplified	  using	  Taq	  DNA	  polymerase	   (Roche)	   in	  a	   total	  
volume	  of	  25	  µl.	  Amplification	  was	  performed	  by	  initial	  denaturation	  at	  95°C	  for	  15	  minutes,	  followed	  by	  35	  
cycles	  of	  denaturation	  at	  95°C	  for	  30	  seconds,	  annealing	  at	  56°C	  for	  45	  seconds,	  extension	  at	  72°C	  for	  45	  
seconds,	  and	  a	   final	  extension	  at	  72°C	   for	  5	  minutes.	  After	  PCR	  amplification,	   the	  samples	  were	  purified,	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directly	  sequenced	  and	  analysed	  according	  to	  the	  ABI	  BigDye	  Terminator	  Cycle	  Sequencing	  protocol	  and	  the	  
automatic	   genetic	   analyser	   ABI3730xl	   (Applied	   Biosystems).	   Results	   were	   analysed	   using	   SeqPilot	   (JCI	  
Medical	  Systems).	  
Deletions	   and	   duplications	   were	   analysed	   using	   the	  multiplex	   ligation	   probe	   amplification	   (MLPA)	   assay	  
MODY	  P241	  kit	  (MRC-­‐Holland).	  This	  kit	  includes	  probes	  for	  all	  nine	  exons	  of	  HNF1B.	  Fragment	  analysis	  was	  
carried	  out	  using	  standard	  methods	  on	  the	  genetic	  analyzer	  ABI3730xl	  (Applied	  Biosystems).	  Results	  were	  
analysed	  using	  Genemarker	  Software	  (Softgenetics).	  	  
Stop-­‐	  and	  splice	  mutations	  are	  considered	  pathogenic;	  missense	  mutations	  were	  considered	  significant	   if	  
either	   they	  were	   reported	   in	   the	   literature	   in	  association	  with	   the	  pathological	  phenotype	   (Human	  Gene	  
Mutation	  Database,	  HGMD)	  or	  in	  case	  of	  de	  novo	  variants,	  if	  there	  was	  a	  change	  in	  an	  amino	  acid	  of	  HNF1	  β	  
and	  segregation	  analysis	   showed	  the	  absence	  of	   this	  variant	   in	  healthy	   family	  members	  and/or	  based	  on	  
phylogenetic	  conservation	  predictions	  (SIFT,	  Polyphen2,	  Mutation	  Taster).	  
Ethics	  
This	  study	  has	  been	  approved	  by	  the	  local	  ethical	  committee	  and	  has	  been	  performed	  in	  accordance	  with	  
the	  ethical	  standards	  laid	  down	  in	  the	  1964	  Declaration	  of	  Helsinki.	  All	  patients	  (or	  legal	  custodians	  in	  case	  
of	   children	  under	  16)	  gave	   their	   informed	  consent	  prior	   to	   their	   inclusion	   in	   the	   study	  and	  children	  gave	  
informed	  assent	  if	  possible.	  
Statistical	  analysis	  
Contingency	   tables	   were	   calculated	   for	   the	   HNF1B	   groups	   with	   predictive	   variables	   to	   test	   bivariate	  
frequency	  distributions.	  We	  used	  Fisher’s	  Exact	  test	  for	  2x2	  tables	  and	  Fisher-­‐Freeman-­‐Halton	  Exact	  test	  for	  
all	   other	   table	   formats	   in	   case	   of	   low	  expected	   counts	   (<5)	   and	   Pearson	  Chi-­‐square	   tests	   otherwise.	   If	   a	  
significant	  difference	  in	  frequency	  distribution	  was	  found,	  we	  made	  pair	  wise	  comparisons	  for	  each	  of	  the	  
categories	  of	   the	  predictive	   variables	  using	   a	   z-­‐test	  with	  Bonferroni	   correction	   (α=0.05).	  Additionally,	  we	  
used	   continuous	   predictive	   variables	   that	   were	   first	   tested	   against	   the	   null	   hypothesis	   of	   normal	  
distribution	  using	  Shapiro	  Wilk	   test	   (α=0.05).	   If	  disproved,	   the	  non-­‐parametric	  Mann-­‐Whitney	  U	   test	  was	  
used	  to	  compare	  the	  mean	  scores	  of	  the	  two	  groups.	   If	  approved	  the	  equality	  of	  variance	  of	  both	  groups	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was	  assessed	  using	  Levene’s	  test	  (α=0.05)	  and	  based	  on	  the	  result	  the	  appropriate	  value	  of	  the	  Student’s	  t-­‐
test	  was	  calculated	  (α=0.05).	  Variables	  yielding	  significant	  differences	  in	  frequency	  distributions	  and	  mean	  
scores	  were	  then	  used	  in	  a	  binary	  logistic	  regression	  model	  to	  calculate	  the	  probability	  of	  the	  occurrence	  of	  
HNF1B	   mutations.	   Continuous	   variables	   were	   coded	   using	   age-­‐related	   critical	   values.	   Results	   were	  
considered	  significant	  if	  p	  <	  0.05.	  All	  analyses	  were	  performed	  using	  IBM	  SPSS	  Statistics	  22.	  
	  
RESULTS	  	  
Using	  the	  selection	  criteria	  described	  in	  Table	  1,	  we	  found	  HNF1B	  mutations	  in	  10%	  of	  patients	  (n=20,	  8.2%	  
children	  and	  14.3%	  adults).	  All	   reported	  cases	  were	   index	  cases.	  Data	  on	  patients	  with	  HNF1B	  mutations	  
are	  summarized	  in	  Table	  2.	  	  Comparison	  between	  clinical,	  laboratory	  and	  imaging	  characteristics	  in	  patients	  
with	  and	  without	  HNF1B	  mutations	  is	  shown	  in	  Table	  3	  and	  4.	  There	  were	  no	  significant	  differences	  in	  the	  
presence	  of	  the	  antenatal	  diagnosis	  in	  the	  mutated	  and	  non-­‐mutated	  groups.	  	  
	  
Mutational	  analysis	  
The	  most	   frequent	  mutation	  was	   a	   heterozygous	   deletion	   of	   the	  HNF1B	   gene	   detected	   in	   50%	  of	   cases.	  
Other	  mutations	  were	  a	  duplication	  (1	  patient	  –	  full	  gene	  duplication)	  or	  single	  base	  pair	  substitutions	  (6	  –	  
only	   5	   different	   –	  missense	  mutations,	   1	   nonsense	   (stop)	  mutation,	   1	   splice	  mutation	   and	   1	   frame	   shift	  
mutation)	  (Table	  2,	  Supplementary	  Table	  1).	  We	  found	  no	  correlation	  between	  the	  types	  of	  mutation,	  the	  
age	  of	  the	  diagnosis	  and	  the	  severity	  of	  renal	  phenotype	  or	  kidney	  function.	  Positive	  familial	  history	  of	  renal	  
disease	  and/or	  diabetes	  and/or	  gout	  was	  found	  with	  similar	  frequency	  in	  patients	  with	  or	  without	  HNF1B	  
mutations.	   Eight	   mutations	   were	   de	   novo	   (all	   full	   gene	   deletions),	   in	   5	   cases	   familial	   analysis	   was	   not	  
available	  and	  in	  7	  cases	  the	  mutation	  was	  inherited.	  In	  these	  inherited	  cases,	  57%	  of	  carrier	  parents	  were	  
also	  affected	  and	  siblings	  were	  affected	  in	  14%	  of	  these	  cases.	  
Renal	  anomalies	  
In	   line	  with	   results	  of	   the	  previous	  studies	   [8,	  10,	  12],	   in	  our	  cohort	  all	  patients	  having	  HNF1B	  mutations	  
were	  diagnosed	  with	  bilateral	  renal	  abnormalities	  (Table	  3).	  The	  most	  frequent	  major	  anomaly	  were	  cysts	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from	   unknown	   origin,	   which	   were	   detected	   in	   65%.	   The	   presence	   of	   two	   or	   more	   major	   renal	   criteria	  
increased	   the	   risk	   to	   find	   HNF1B	   mutation	   by	   factor	   2	   (Figure	   1).	   Interestingly,	   fetal	   “bright”	   hyper-­‐
echogenic	  kidneys	  described	  in	  other	  cohorts	  were	  not	  found	  in	  our	  HNF1B–mutated	  patients,	  while	  they	  
were	  present	   in	  5/185	  of	  patients	  without	  HNF1B	  mutations:	  however,	   the	   information	  about	   fetal	   renal	  
ultrasound	  was	  not	  available	  in	  all	  adult	  patients.	  Thus,	  isolated	  minor	  renal	  anomalies	  are	  rather	  predictive	  
for	   the	  negative	  HNF1B	   analysis	   (p=0.05).	   	  Unexpectedly,	  hyperuricosemia	   reported	   in	  other	  cohorts	  was	  
not	   predictive	   for	   finding	   HNF1B	  mutation	   and	  was	   present	   only	   in	   4	   of	   the	  HNF1B+	   patients.	   The	   only	  
biochemical	   parameter	   associated	  with	  HNF1B	  mutations	  was	  hypomagnesaemia	   found	   in	  5/20	   (25%)	  of	  
the	  HNF1B	   positive	   patients	   compared	   to	   5%	   of	  HNF1B	   negative	   patients	   (p=0.008)	   (Table	   4).	   Although	  
altered	   creatinine	   clearance	   was	   not	   predictive	   for	   finding	   HNF1B	   mutations,	   it	   was	   decreased	   (<90	  
ml/min/1.73	  m2)	   in	   8/12	   children	   and	   in	   5/8	   adults.	   One	   patient	   underwent	   combined	   kidney-­‐pancreas	  
transplantation	  one	  year	  after	  diagnosis.	  	  
Extra-­‐renal	  anomalies	  
Diabetes	  mellitus	   was	   diagnosed	   in	   0/12	   children	   and	   5/8	   adults	   having	  HNF1B	   mutations	   compared	   to	  
0/143	  and	  5/42	  children	  and	  adults	  without	  a	  HNF1B	  mutation	  respectively,	  however,	  it	  was	  not	  predictive	  
for	  finding	  the	  mutation.	  Liver	  enzyme	  abnormalities	  were	  detected	  in	  2/12	  and	  in	  2/8	  children	  and	  adults	  
with	  HNF1B	  mutation,	  with	  the	  frequencies	  being	  comparable	  to	  not-­‐mutated	  patients.	  	  
	  
Relative	  risk	  for	  finding	  HNF1B	  mutations	  
Relative	  risk	   for	   finding	  HNF1B	  mutations	  was	  highest	   for	  patients	  having	  cysts	   from	  unknown	  origin	   (6.1	  
(95%	  CI	  [2.50,	  15.01];	  p<0.001)	  followed	  by	  hypomagnesaemia	  (4.2	  (95%	  CI	  [1.78,	  10.03];	  p=0.001)	  and	  two	  











The	  described	  phenotypic	  spectrum	  of	  CAKUT	  associated	  with	  HNF1B	  mutations	  is	  broad	  and	  encompasses	  
renal	  cysts	  in	  patients	  typically	  having	  normal	  or	  decreased	  kidney	  size,	  solitary	  functioning	  kidneys,	  renal	  
hypo/dysplasia,	   glomerulocystic	   disease,	   oligomeganephronia,	   hydronephrosis,	   pyeloureteral	   junction	  
stenosis	   and	   VUR	   [8,	   10,	   13].	   With	   the	   exception	   of	   patients	   carrying	   large	   deletions,	   no	   genotype-­‐
phenotype	   correlations	   have	   been	   demonstrated	   so	   far;	   even	   carriers	   of	   the	   same	   inherited	   mutation	  
within	  one	  family	  can	  have	  different	  clinical	  presentations	  complicating	  the	  developing	  of	  screening	  criteria	  
for	  the	  HNF1B	  mutational	  analysis.	  Because	  of	  the	  high	  prevalence	  (~10	  to	  30%)	  of	  HNF1B	  mutations	  found	  
in	  different	  CAKUT	  cohorts	  [8,	  10-­‐13],	  this	  gene	  is	  analysed	  most	  frequently	  in	  CAKUT	  patients.	  	  
In	  our	  study,	  we	  used	  the	  criteria	  previously	  published	   in	  the	   literature.	  Ulinski	  et	  al.	   [10]	   tested	  children	  
based	   on	   the	   presence	   of	   renal	   cysts,	   hyperechogenicity,	   hypoplasia	   or	   single	   kidney	   and	   found	  HNF1B	  
mutations	   in	   31%.	   The	   same	   criteria	   (with	   MCDK	   and	   hyperuricemic	   tubulointerstitial	   nephropathy	   in	  
addition)	  were	  used	  by	  Heidet	  et	  al.	  [8]	  with	  a	  mutation	  detection	  rate	  of	  20%.	  Decramer	  et	  al.	  [13]	  based	  
their	   screening	  on	   the	  diagnosis	  of	   fetal	  bilateral	  hyperechogenic	  kidneys	  and	   found	  HNF1B	  mutations	   in	  
29%	  of	  the	  patients.	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In	   our	   hospital,	   using	   the	   criteria	  mentioned	   above,	  HNF1B	   analysis	  was	   prospectively	   performed	   in	   205	  
patients	  over	  a	  3	  years	  period	  and	  yielded	  20	  positive	  cases.	  The	  frequency	  of	  HNF1B	  mutations	  was	  slightly	  
lower	  compared	  to	  previously	  published	  cohorts,	  most	  likely	  due	  to	  the	  prospective	  character	  of	  our	  study	  
limiting	   the	  selection	  bias.	  Moreover,	  all	   cases	   reported	   in	   the	  current	   study	  were	   index	  cases	  using	  pre-­‐
defined	  clinical	  criteria,	  and	  the	  family	  members	  detected	  by	  the	  family	  screening	  were	  not	  included	  in	  the	  
analysis,	  irrespectively	  whether	  they	  had	  CAKUT	  anomalies	  
The	   severity	  of	   renal	   and	  extra-­‐renal	  phenotype	  did	  not	  differ	   significantly	  between	  paediatric	   and	  adult	  
patients	  and	  there	  was	  no	  correlation	  between	  the	  type	  of	  the	  mutation,	  the	  age	  of	  the	  diagnosis	  and	  the	  
creatinine	  clearance,	  although	  renal	  dysplasia	  was	  the	  most	  frequently	  renal	  anomaly	  in	  children	  and	  cysts	  
of	   unknown	   origin	   in	   adults.	   This	   indicates	   that	   adult	   patients	   with	   well-­‐defined	   phenotype	   fitting	   the	  
screening	  criteria	  have	  to	  be	  rigorously	  tested	  for	  HNF1B	  mutations	  as	  this	  has	  direct	  medical	  consequences	  
for	  the	  patients.	  In	  this	  regard,	  the	  high	  risk	  of	  post-­‐transplant	  onset	  of	  diabetes	  mellitus	  in	  HNF1B	  positive	  
patients	   should	   be	   carefully	   considered	   [18].	   Furthermore,	   recently	   demonstrated	   association	   between	  
HNF1B	   expression	   levels	   and	   certain	   types	   of	   cancers	   (ovarian,	   endometrial,	   prostate,	   liver)	   necessitates	  
careful	  follow-­‐up	  of	  these	  patients	  [2,	  19-­‐22].	  Gynaecological	  examination	  and	  follow-­‐up	  are	  recommended	  
in	   females	   with	   HNF1B	   mutations,	   since	   uterine	   abnormalities	   are	   common	   (2	   out	   of	   3	   adult	   female	  
patients	   in	   our	   cohort	   had	   a	   uterine	   abnormality).	  Moreover,	   the	   dominant	   inheritance	   of	   the	  mutation	  
should	  be	  taken	  into	  account	  for	  counselling	  of	  the	  families.	  	  
Interestingly,	   in	   our	   cohort	   of	   HNF1B	   mutated	   patients,	   we	   didn’t	   had	   indications	   for	   overt	   pancreas	  
dysfunctions,	   however,	   some	   mild	   subclinical	   anomalies	   cannot	   be	   excluded.	   For	   example,	   elastase	  
deficiency	  can	  be	  present	  in	  the	  absence	  of	  clinical	  symptoms	  in	  patients	  with	  pancreas	  hypoplasia	  [23,	  24].	  
Our	  study	  indicates	  that	  the	  number	  of	  screened	  patients	  can	  be	  reduced	  without	  missing	  cases	  (Figure	  1).	  
Based	   on	   our	   results,	   we	   propose	   to	   restrict	   HNF1B	   genetic	   analysis	   to	   patients	   having	   bilateral	   renal	  
anomalies,	   in	   particular,	   renal	   dysplasia	   and	   cysts	   of	   unknown	   origin.	   A	   combination	   of	   two	  major	   renal	  
anomalies	   increases	   the	   likelihood	   of	   finding	   the	   mutation	   by	   factor	   2,	   and	   an	   associated	  
hypomagnesaemia	   by	   factor	   4.	  HNF1B	   analysis	   should	   be	   considered	   in	   all	   patients	   fitting	   these	   criteria	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irrespectively	  of	  age	  at	  presentation,	  extra-­‐renal	   symptoms	  or	   the	  presence	  of	  affected	   family	  members.	  
Screening	   should	   be	   discouraged	   if	   there	   are	   isolated	   unilateral	   renal	   abnormalities	   or	   an	   absence	   of	   a	  
major	   criterion.	   The	   use	   of	   these	   criteria	   in	   our	   cohort	   would	   reduce	   the	   amount	   of	   patients	   requiring	  
genetic	  analysis	  by	  50%	  without	  any	  missing	  cases.	  The	  incidence	  of	  HNF1B	  mutations	  would	  increase	  from	  
10%	  to	  19%	  implicating	  a	  major	  reduction	  in	  screening	  costs.	  
Recently	  Faguer	  et	  al.	  [25]	  developed	  a	  17-­‐items	  score	  for	  selecting	  patients	  for	  HNF1B	  mutational	  analysis	  
and	   tested	   it	   in	  a	   large	  cohort	  of	  433	   individuals	   containing	  56	  mutated	  cases.	  The	  score	  of	  ≤8	   ruled	  out	  
HNF1B	  mutations	  with	  a	  sensitivity	  of	  98.2%	  and	  a	  specificity	  of	  41.1%.	  	  We	  applied	  this	  score	  to	  our	  cohort	  
and	   found	   that	   this	  would	   reduce	   the	  number	  of	  patients	  eligible	   for	   the	   screening	   to	  55,	  but	  we	  would	  
miss	  3	  out	  of	  20	  patients	  with	  HNF1B	  mutations	  (patients	  7,	  8,	  10	  in	  Table	  2	  and	  Supplementary	  Table	  1).	  
These	  patients	  lacked	  a	  clear	  family	  history,	  had	  bilateral	  dysplasia	  ‘only’	  (patient	  8	  and	  10)	  or	  dysplasia	  and	  
agenesis	   (patient	   7)	  without	   electrolyte	   abnormalities,	   cysts,	   pancreas	   abnormalities	  or	  other	   extra-­‐renal	  
manifestations	  which	  result	  in	  the	  Faguer-­‐score	  with	  a	  maximum	  of	  6	  (while	  8	  was	  necessary	  for	  screening	  
HNF1B	  in	  their	  cohort).	  In	  contrast,	  these	  patients	  would	  have	  been	  screened	  in	  our	  restricted	  protocol.	  	  
Interestingly,	  two	  	  patients	  (patients	  7	  and	  10	  in	  Table	  2	  and	  Supplementary	  Table	  1)	  in	  our	  cohort	  having	  
low	  Faguer’s	  scores,	  had	  a	  missense	  mutation	  and	  one	  patient	  has	  a	  duplication	  of	  the	  HNF1B	  gene	  (patient	  
8).	  Based	  on	   in	  silico	  prediction	   tools	   	  (SIFT	   [26]	  and	  PolyPhen2	   [27]),	   the	  conservation	  of	   the	  amino	  acid	  
and	  the	  population	  frequency	  observed	  in	  different	  variant	  databases	  (dbSNP	  [28],	  ESP	  [29],	  GoNL	  [30],	  our	  
in-­‐house	  database	  (which	  consists	  of	  384	  unaffected	  and	  unrelated	  parents,	  unrelated	  oncology	  patients),	  
the	   c.1640C>T	   (p.S547F)	   is	   considered	   to	   be	   likely	   pathogenic	   (Supplementary	   Table	   1).	   There	   is	   some	  
skepticism	  towards	  the	  pathogenicity	  of	  the	  variant	  c.226G>T	  (p.G76C),	  since	  this	  variant	  was	  observed	  in	  2	  
unrelated	  families,	  but	   is	  also	  present	  at	  a	   frequency	  of	  0.02%	   in	  the	  European	  American	  population	  [29,	  
31].	  Segregation	  analysis	  in	  large	  families	  might	  shed	  light	  on	  the	  role	  of	  this	  variant.	  Concerning	  the	  third	  
variant,	  the	  duplication	  of	  HNF1B,	  this	  is	  a	  rare	  event	  in	  comparison	  to	  the	  deletion	  of	  the	  complete	  HNF1B	  
gene.	  Faguer	  et	  al.	  [32]	  also	  described	  a	  patient	  with	  a	  17q12	  chromosomal	  duplication,	  accompanying	  the	  
HNF1B	  gene,	  associated	  with	  renal	  disease.	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Our	   screening	   criteria	   compared	   to	   those	   of	   Faguer	   et	   al.	   are	   less	   specific,	   but	   are	  more	   applicable	   for	  
routine	  clinical	  practice,	  where,	  for	  example	  prenatal	  history,	  information	  on	  pathological	  specimen	  of	  the	  
kidney	  and	  full	  anatomical	  information	  on	  kidneys	  and/or	  pancreas	  are	  often	  lacking.	  	  
The	  spectrum	  of	  mutations	  found	  in	  our	  cohort	  was	  comparable	  to	  already	  published	  studies	  with	  de	  novo	  
deletions	  being	  the	  most	  prevalent	  type	  of	  mutations	  [8,	  25,	  33,	  34].	  Interestingly,	  screening	  of	  the	  family	  
members	  revealed	  5/13	  asymptomatic	  parents	  of	  the	  children	  and	  2/7	  asymptomatic	  parents	  of	  the	  adults	  
pointing	   to	   the	   extreme	   phenotypic	   variability	   and	   questioning	   the	   pathogenicity	   of	   the	   mutations.	  
However,	  among	  these	  cases	  3/7	  mutations	  have	  been	  previously	  reported	  in	  association	  with	  the	  clinical	  
phenotype	  (Table	  2)	  or	  were	  predicted	  being	  pathogenic	  by	  prediction	  programs.	  	  
The	   phenotypic	   variability	   in	   patients	  with	  HNF1B	  mutations	   is	   not	   fully	   understood.	   During	  mammalian	  
kidney	  development,	  HNF-­‐1β	  is	  expressed	  in	  the	  Wolffian	  duct	  and	  metanephric	  mesenchyme	  starting	  from	  
the	   renal	   vesicle	   stage	   [35,	   36].	   	   Embryonic	   lethality	   of	   Hnf1b	   knock-­‐out	   mouse	   model	   due	   to	   visceral	  
endoderm	   defects	   hindered	   studying	   its	   regulatory	   role	   in	   nephrogenesis	   [37].	   Subsequent	   strategies	  
undertaken	   to	   overcome	   this	   problem	   revealed	   the	   pivotal	   role	   of	   the	   gene	   in	   ureteric	   bud	   branching	  
involving	  Wnt9b	  signaling.	  Recent	  studies	  in	  zebra	  fish	  mesonephros	  identified	  Hnf1b	  as	  a	  major	  regulator	  
of	  proximo-­‐distal	  tubular	  segmentation	  [38].	  Transcriptional	  targets	  of	  HNF1β	  in	  mice	  include	  several	  genes	  
involved	   in	   renal	   cystic	   disease	   such	   as	   Pkhd1,	   Pkd2,	   Pkd1,	   Umod,	   Inf88,	   Kif3a,	   TMEM27	   [39-­‐42],	   and	  
prenatal	  Hnf1b	  inactivation	  in	  the	  developing	  kidney	  resulted	  in	  severe	  polycystic	  disease	  [42,	  43].	  Inducible	  
inactivation	  of	  Hnf1b	  in	  mice	  after	  10	  days	  of	  birth	  didn’t	  cause	  cystic	  lesions	  suggesting	  that	  cyst	  formation	  
is	   linked	   to	   the	   morphogenetic	   proliferation	   [42].	   Interestingly,	   when	   Hnf1b	   tubules	   were	   forced	   to	  
regenerate	   by	   inducing	   ischemia-­‐reperfusion	   injury,	   cyst	   formation	   could	   be	   stimulated	   even	   when	   the	  
gene	  was	  inactivated	  after	  completed	  kidney	  development	  [42]	  signifying	  that	  the	  heterogeneity	  of	  HNF1b-­‐
associated	  phenotype	  might	  be	  related	  to	  the	  environmental	   factors	  stimulating	  tubular	  proliferation.	   	   In	  
this	  respect,	  high	  prevalence	  of	  renal	  cysts	   found	   in	  our	  adult	  HNF1B	  positive	  patients	   (7/8)	  compared	  to	  
6/12	  children,	  mostly	  having	  renal	  dysplasia,	  might	  support	  this	  pathogenic	  mechanism,	  however,	  to	  which	  
extent	  the	  transcriptional	  network	  if	  Hnf1b	  in	  mice	  can	  be	  extended	  to	  humans	  still	  remains	  unclear.	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The	  epigenetic	   regulation	  of	  HNF1β	   expression	  by	  microRNA’s	   that	  has	   recently	  been	  demonstrated	  also	  
points	   to	   the	   complexity	   of	   the	   regulatory	   up-­‐	   and	   downstream	   pathways	   that	   can	   be	   potentially	  
responsible	  for	  the	  diversity	  of	  the	  phenotype	  (15).	  
The	  explanation	  of	  hypomagnesaemia	   in	  patients	  with	  HNF1B	  mutations	  unravelled	   the	   role	  of	  HNF1β	   in	  
transcription	  of	  genes	  involved	  in	  renal	  magnesium	  handling	  [12,	  39,	  44].	  There	  are	  HNF1β	  binding	  sites	  in	  
the	  FXYD2	  gene,	  encoding	  the	  γ-­‐subunit	  of	  the	  Na(+)/K(+)-­‐ATPase	  and	  mutations	  in	  this	  gene	  are	  linked	  to	  
familial	  autosomal	  dominant	  isolated	  hypomagnesaemia	  [12]	  [45].	  Interestingly,	  analysis	  of	  mRNA	  derived	  
from	  urine	  of	  HNF1B+	  patients	  showed	  no	  altered	  expression	  of	  FXYD2,	  while	  urinary	  excretion	  of	  ATP1A1	  
mRNA	   encoding	   α1-­‐subunit	   of	   the	   Na(+)/K(+)-­‐ATPase	   was	   significantly	   decreased,	   although	   the	   limited	  
availability	  of	  mRNA	  that	   could	  be	  extracted	   from	  the	  urine	   limited	   the	  possibility	   to	  analyse	   the	  various	  
isoforms	   of	   these	   genes	   [37].	   In	   our	   cohort,	   hypomagnesaemia	   was	   found	   in	   5/20	   of	   HNF1B	   positive	  
patients	  (1	  child	  and	  4	  adults),	  suggesting	  that	  it	  might	  be	  a	  later	  manifestation	  of	  the	  disease	  [7,	  8,	  12,	  33].	  	  
Although	   UMOD	   gene	   causing	   familial	   juvenile	   hyperuricemic	   nephropathy	   (FJHN)	   and	   medullary	   cystic	  
kidney	   disease	   (MCKD)	   belongs	   to	   the	   transcriptional	   network	   of	   HNF1B	   [46],	   the	   frequency	   of	  
hyperuricemia	  was	  rather	  low	  in	  our	  cohort	  and	  didn’t	  differ	  between	  HNF1B	  positive	  and	  HNF1B	  negative	  
patients.	  This	  observation	  contrasting	  the	  results	  of	  the	  other	  studies	  [8,	  12]	  might	  be	  explained	  by	  a	  small	  
number	   of	   the	   patients	   and	   a	   relatively	   good	   kidney	   function	   even	   in	   adults.	   On	   the	   other	   hand,	   our	  
findings	   indicate	  that	  normal	  serum	  uric	  acid	   levels	  do	  not	  exclude	  finding	  HNF1B	  mutations	   in	   individual	  
patients.	  	  
In	   summary,	   we	   propose	   to	   restrict	   HNF1B	   genetic	   analysis	   to	   patients	   having	   bilateral	   major	   renal	  
anomalies,	   and	   in	   particular	   cysts	   from	   unknown	   origin	   in	   combination	   with	   hypomagnesaemia.	  HNF1B	  
analysis	  should	  be	  considered	  in	  all	  patients	  fitting	  these	  criteria	  irrespectively	  of	  age	  at	  presentation,	  extra-­‐
renal	   symptoms	   or	   the	   presence	   of	   affected	   family	   members.	   	   In	   awaiting	   widespread	   availability	   of	  
CAKUTome	   screening	   platforms,	   the	   adapted	   criteria	   suggested	   by	   our	   single	   centre	   prospective	   study	  
should	  be	  validated	  in	  larger	  cohorts	  of	  CAKUT	  patients.	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TABLES	  	  
Table	  1:	  Criteria	  for	  inclusion	  
Major	  criteria	   Minor	  criteria	  
Fetal	  bilateral	  hyperechogenic	  kidneys	   Ectopic	  kidney	  
Multicystic	  dysplastic	  kidney	   Vesico-­‐ureteral	  reflux	  
Renal	  agenesis	   Hydronephrosis	  
Hypoplastic	  or	  dysplastic	  kidneys	   	  
Cysts	  from	  unknown	  origin	   	  
Extrarenal	  criteria	   Positive	  familial	  history	  
Diabetes	  mellitus	   Abnormalities	  in	  kidney	  
Hypomagnesaemia	  
Hypokalemia	  
Abnormalities	  in	  urogenital	  tract	  
Gout	  
Hyperuricemia	   Liver	  function	  abnormalities	  
Liver	  function	  abnormalities	   	  Diabetes	  or	  exocrine	  pancreas	  dysfunction	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
